Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Sarcomas

Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study

Bone Marrow Transplantation volume 45, pages 1234–1238 (2010)Cite this article

Abstract

Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, single-institutional phase II study that enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease. After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n=9); all other patients continued chemotherapy for two more cycles. After standard chemotherapy, PR (n=10), stable disease (SD, n=6) and progressive disease (PD, n=14) were attained for the evaluable patients. Twenty-nine patients died and five are alive with the disease. Median PFS was 11.6 months (range 8–15) for patients treated with high-dose chemotherapy (n=9) vs 5.6 months (range 0–19) for patients treated with standard chemotherapy. Median OS was 23.7 months (range 12–34) vs 10.8 months (range 0–39), respectively. The subgroup of patients treated with high-dose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R et al. Prognostic factors in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999; 17: 150–157.

    Article  CAS  PubMed  Google Scholar 

  2. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R et al. Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537–1545.

    Article  CAS  PubMed  Google Scholar 

  3. Bui NB, Demaille MC, Chevreau C, Blay JY, Cupissol D, Rios M et al. qMAID vs MAID+25% in adults with advanced soft tissue sarcoma (STS): first results of a randomized study of the FNCLCC Sarcoma Group. Proc Am Soc Clin Oncol 1998; 17: 517a (abstract 1991).

    Google Scholar 

  4. Blay JY, van Glabbeke M, Nielsen OS, van Oosterom AT, Tursz T, Oosterhuis JW et al. Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: a study on 1742 patients (STBSG). Proc Am Soc Clin Oncol 1998; 17: 512a (abstract 1973).

    Google Scholar 

  5. Verweij J, Mouridsen HT, Nielsen OS, Woll PJ, Somers R, van Oosterom AT et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995; 20: 193–201.

    Article  CAS  PubMed  Google Scholar 

  6. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350: 1647–1654.

  7. Bramwell VH, Anderson D, Charette ML . Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma 2000; 4: 103–112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies —dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378–2384.

    Article  CAS  PubMed  Google Scholar 

  9. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M . A systemic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573–581.

    Article  Google Scholar 

  10. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M . Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Meta-analysis of ifosfamide based chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008; 34: 339–347.

    Article  CAS  PubMed  Google Scholar 

  11. Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: a Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997; 33: 1551–1558.

    Article  CAS  PubMed  Google Scholar 

  12. Jelic S, Kovcin V, Milanovic N, Babovic N, Kreacic M, Ristovic Z et al. Randomised study of high-dose epirubicin versus high-dose epirubicin–cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33: 220–225.

    Article  CAS  PubMed  Google Scholar 

  13. Reichardt P, Tilgner J, Hohenberger P, Dorken B . Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16: 1438–1443.

    Article  CAS  PubMed  Google Scholar 

  14. Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221–1227.

    Article  CAS  PubMed  Google Scholar 

  15. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: 373–379.

    CAS  PubMed  Google Scholar 

  16. Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, Chauvin F et al. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 1992; 10: 405–408.

    CAS  PubMed  Google Scholar 

  17. Mesia R, Sola C, Lopez Pousa A, Mendoza L, Bellet M, Andres L et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 1994; 194: 960–965.

    CAS  PubMed  Google Scholar 

  18. Seynaeve C, Verweij J . High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol 1999; 26: 119–133.

    CAS  PubMed  Google Scholar 

  19. Elias AD . High-dose therapy for adult soft tissue sarcoma: dose response and survival. Semin Oncol 1998; 25: 19–23 and 45–48.

    CAS  PubMed  Google Scholar 

  20. Reichardt P . High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002; 41: 157–167.

    Article  PubMed  Google Scholar 

  21. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P . High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643–3650.

    Article  CAS  PubMed  Google Scholar 

  22. Ray-Coquard I, Biron P, Blay JY . High-dose chemotherapy in soft tissue sarcomas of adults. Bull Cancer 2001; 88: 858–862.

    CAS  PubMed  Google Scholar 

  23. Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Koscileniak E et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 2002; 41: 129–140.

    Article  PubMed  Google Scholar 

  24. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahmen S, Licht T, Baumert J et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2006; 71: 32–39.

    Article  CAS  PubMed  Google Scholar 

  25. Binh NN, Chevreau C, Penel N, Bay J, Coindre J, Mathoulin-Pelissier S et al. Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): a randomized trial from FNCLCC—French Sarcoma Group. J Clin Oncol 2009; 27: 15S (abstract 10505).

    Article  Google Scholar 

  26. Reichardt P, Verweij J, Crowther D . Current controversies in cancer: should high-dose chemotherapy be used in the treatment of soft-tissue sarcoma? Eur J Cancer 1997; 33: 1351–1360.

    Article  CAS  PubMed  Google Scholar 

  27. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004; 34: 37–41.

    Article  CAS  PubMed  Google Scholar 

  28. Kasper B, Ho AD, Egerer G . Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology 2005; 68: 115–121.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    B Kasper, T Schmitt, P Wuchter, S Dietrich, A D Ho & G Egerer

  2. Lungenklinik Merheim, Kliniken der Stadt Köln, Köln, Germany

    I Scharrenbroich

Authors
  1. B Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Scharrenbroich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Wuchter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A D Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Egerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Kasper.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kasper, B., Scharrenbroich, I., Schmitt, T. et al. Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. Bone Marrow Transplant 45, 1234–1238 (2010). https://doi.org/10.1038/bmt.2009.333

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.333

Keywords

This article is cited by

Search

Advanced search

Quick links